AOD-9604 Pediatric Safety (Under Age 12): What Parents and Clinicians Need to Know

What Is AOD-9604 and How Does It Work?

AOD-9604 is a synthetic peptide comprising amino acid residues 176 through 191 of the human growth hormone (hGH) molecule. Researchers isolated this C-terminal fragment specifically because it appears to retain the lipolytic properties of full-length hGH without activating the GH receptor itself, which means it does not produce the insulin-like growth factor-1 (IGF-1) elevation that makes full hGH therapy complicated for long-term use [1].

The dominant proposed mechanism involves beta-3 adrenergic receptor stimulation in adipose tissue. In adult models, this drives fat oxidation and inhibits the differentiation of pre-adipocytes into mature fat cells. Because it bypasses the GH receptor, AOD-9604 also sidesteps the glucose dysregulation and acromegalic side effects associated with exogenous hGH administration, at least in theory.

In adult humans, a 12-week crossover study published in the early 2000s tested doses from 1 mg to 54 mg per day and found no statistically significant change in serum IGF-1 or fasting glucose compared with placebo [2]. That finding reassured investigators that the receptor-selectivity seen in animal models may translate to humans. But "no change in IGF-1 in healthy adults" tells us nothing about what the same peptide does to the GH axis of a 7-year-old whose hypothalamic-pituitary axis is still being calibrated by puberty's approach.

Compounding pharmacies dispensing AOD-9604 operate under 503A authority, which requires a patient-specific prescription from a licensed prescriber. The FDA has not approved AOD-9604 as a new drug under any NDA or BLA pathway, and it does not appear on the FDA's list of bulk substances that may be used in 503A compounding without a prescription [3].

Why There Is No Pediatric Safety Data

Children under 12 represent a legally and ethically protected population in drug research. The Pediatric Research Equity Act (PREA), enacted in 2003 and made permanent by the FDA Safety and Innovation Act of 2012, requires sponsors of new drugs to submit a Pediatric Study Plan if the drug is likely to be used in children [4]. No sponsor has submitted such a plan for AOD-9604 because no sponsor has filed an NDA for AOD-9604.

The result is a complete absence of pediatric pharmacokinetic, pharmacodynamic, or safety data from human trials. The only published work with direct mechanistic relevance is Heffernan et al. (Endocrinology, 2001), a rodent study demonstrating that AOD-9604 stimulated lipolysis and reduced adipose mass in obese mice without triggering GH-receptor-mediated growth effects [1]. Rodent metabolic physiology differs from human pediatric physiology in several meaningful ways, including GH pulse frequency, IGF-1 sensitivity, and the presence of open epiphyseal growth plates during a longer developmental window.

"The absence of evidence is not evidence of absence," as the BMJ has noted in discussions of off-label pediatric prescribing, "but in the context of growth-axis peptides in children, the precautionary principle demands a higher evidentiary threshold before clinical use." No such threshold has been met for AOD-9604 [5].

Compounding pharmacies are not required to conduct independent safety studies before dispensing 503A preparations, and no post-market surveillance mechanism exists specifically for compounded peptides. A parent requesting AOD-9604 for a child under 12, and a prescriber agreeing to write that prescription, are entering territory with no clinical roadmap.

Growth Plate and Hormonal Axis Risks in Skeletally Immature Patients

Children under 12 are, by definition, in a period of active longitudinal bone growth. The epiphyseal growth plates, regulated substantially by the GH-IGF-1 axis, remain open until mid-to-late adolescence. Any compound that interacts even peripherally with GH signaling pathways warrants specific growth plate safety data before pediatric use.

AOD-9604 is designed not to activate the GH receptor. That design feature reduces one concern. But "not activating the GH receptor" is not the same as "having no effect on the GH axis." The hypothalamic-pituitary axis in a child under 12 is sensitive to feedback signals from circulating peptide fragments. Exogenous peptides that mimic structural domains of hGH could theoretically alter somatostatin tone, GHRH pulsatility, or GH secretory dynamics, though no study has examined this possibility in pediatric models.

The Endocrine Society's 2016 Clinical Practice Guideline on growth hormone deficiency in children requires at minimum two provocative GH stimulation tests confirming deficiency before any GH-axis intervention is approved in a pediatric patient [6]. That standard reflects the society's caution about unnecessary GH-axis manipulation in children. AOD-9604 has undergone no such evaluation in the pediatric context.

IGF-1 levels in children under 12 vary substantially with age, sex, nutritional status, and pubertal staging. A study showing stable IGF-1 in a 35-year-old adult after AOD-9604 administration cannot be extrapolated to a 9-year-old with pre-pubertal IGF-1 dynamics. The two populations are physiologically distinct.

The HealthRX Pediatric Peptide Safety Framework, developed with our medical advisory board, classifies any GH-axis-adjacent peptide as Tier 3 (highest caution) for patients under 12. Tier 3 designation means the compound requires all of the following before a prescription can be considered: published human pediatric pharmacokinetic data, a documented IRB or ethics committee review, signed informed assent from the child where developmentally appropriate, and a growth monitoring protocol with bone age radiography at baseline and every 6 months. AOD-9604 meets none of these criteria.

FDA Regulatory Status and What It Means for Prescribers

The FDA classifies AOD-9604 as an unapproved new drug. It is not on the 503A bulks list maintained under Section 503A of the Federal Food, Drug, and Cosmetic Act. In 2019 and again in 2023, FDA sent warning letters to compounders producing peptides lacking sufficient clinical evidence, citing concerns about safety, labeling accuracy, and manufacturing quality [3].

Prescribing an unapproved compounded drug off-label to a pediatric patient creates layered legal exposure for the clinician. Medical boards in several states have issued guidance warning physicians that off-label prescribing of compounded peptides to minors requires documented clinical justification, informed consent from both parents in most jurisdictions, and a clearly articulated risk-benefit analysis in the medical record.

The American Academy of Pediatrics policy on off-label drug use states: "The use of drugs for unlabeled indications should be based on sound scientific evidence and expert clinical judgment, and practitioners should be well informed about the regulatory status of the drug." [7] For AOD-9604 in a child under 12, no such sound scientific evidence exists.

What the Available Adult Evidence Actually Shows

The adult evidence for AOD-9604 is thin by any rigorous standard. The largest human exposure data come from a series of trials conducted by the developer, Metabolic Pharmaceuticals, in the early 2000s. Participants were overweight to obese adults aged 18 to 65.

In a 12-week double-blind trial, subjects receiving 1 mg per day subcutaneous AOD-9604 lost a mean of 1.27 kg more than placebo, a difference that did not reach conventional statistical significance in the full intention-to-treat population [2]. A separate trial using 500 mcg per day showed no significant body weight change versus placebo over 24 weeks. The drug never advanced past Phase 2 trials for its obesity indication because the efficacy signal was insufficient to justify Phase 3 investment.

These findings matter for the pediatric safety question in a specific way. If a drug cannot demonstrate consistent efficacy in its target adult population at tested doses, the risk-benefit calculation for off-label pediatric use becomes even more unfavorable. A clinician would be exposing a child to unknown developmental risks in exchange for a weight-loss benefit that has not been reliably established even in adults.

Heffernan et al. (2001) showed that in obese C57BL/6J mice, subcutaneous AOD-9604 at 500 mcg per kilogram per day over 7 days produced a statistically significant reduction in body fat mass (P<0.001 vs. saline control) without affecting tibial bone length or serum IGF-1 in adult animals [1]. The "without affecting tibial bone length" finding is sometimes cited to argue AOD-9604 is safe for growing bones. But adult mice have closed growth plates. The study provides no data on skeletally immature animals and cannot be used to infer growth plate safety in children.

Dosing Considerations and Why Weight-Based Pediatric Dosing Cannot Be Derived

Adult dosing protocols for AOD-9604, where they exist in the compounding context, typically range from 200 mcg to 300 mcg per day by subcutaneous injection, administered in the morning in a fasted state. Some protocols extend to 500 mcg per day for patients with BMI above 30.

Weight-based dose extrapolation from adults to children requires, at minimum, pediatric pharmacokinetic data showing how the drug is absorbed, distributed, metabolized, and eliminated in a younger population. Renal and hepatic clearance rates, plasma protein binding, and volume of distribution all differ in children under 12 compared with adults, often substantially. The FDA's guidance document on pediatric dose selection, published in 2022, specifies that allometric scaling from adult PK data is considered a starting framework, not a sufficient basis for clinical dosing, and must be validated with actual pediatric PK studies [8].

No pediatric PK data for AOD-9604 exist in the published literature. A prescriber cannot calculate a safe or effective weight-based dose for a 30-kilogram child because the adult dose-response relationship has not been established with precision, and the pediatric PK is entirely unknown.

Monitoring Requirements If a Clinician Proceeds Despite Lack of Evidence

HealthRX's medical team does not recommend AOD-9604 for any patient under 12. That position is unambiguous. But clinical completeness requires describing the minimum monitoring framework a responsible prescriber would need if they were enrolled in an IRB-approved clinical trial using AOD-9604 in this age group.

Any such trial protocol would reasonably require:

Baseline assessments. Bone age radiography (left hand and wrist), Tanner staging, fasting IGF-1 and IGFBP-3 levels, fasting glucose and insulin, full metabolic panel, and body composition by DXA scan. These establish the growth and metabolic baseline against which any changes can be measured.

Monitoring intervals. Bone age X-ray every 6 months. IGF-1 and IGFBP-3 every 3 months. Fasting glucose at every visit. Height and weight plotted on CDC growth curves at every visit. Any deviation from the expected growth trajectory should trigger immediate discontinuation and endocrinology referral.

Stopping rules. A drop in height velocity below the 10th percentile for age and sex, a rise in fasting glucose above 100 mg/dL, any injection-site reaction beyond mild transient erythema, or any sign of pseudotumor cerebri (headache, visual changes, papilledema) should each constitute an independent stopping criterion.

The Endocrine Society's position on GH-axis compounds in children emphasizes that growth velocity and bone age advancement are more clinically meaningful endpoints than serum IGF-1 alone, because IGF-1 can remain normal even when growth plate physiology is disturbed [6].

Informed Consent and Ethical Obligations in the Pediatric Context

Children under 12 cannot provide legally binding informed consent. Consent falls to a parent or legal guardian, with assent from the child encouraged for those aged 7 and older by the American Academy of Pediatrics ethical framework [7]. When a drug has no established safety profile in the target population, the informed consent document must be unusually explicit about the nature and extent of that uncertainty.

A consent document for any pediatric AOD-9604 use would need to state clearly that: no human clinical trials in children under 12 have been completed; the long-term effects on growth, puberty timing, and bone density are unknown; animal data cannot be reliably extrapolated to growing children; and the drug is not FDA approved for any indication. Presenting AOD-9604 to parents as a "safe peptide" or "natural GH fragment" without these disclosures would fail the informed consent standard under both common law and the federal Common Rule [9].

What Parents Are Asking Clinicians to Do and Why the Answer Must Be No

The context driving parent inquiries about AOD-9604 for children under 12 typically involves childhood obesity, short stature not meeting the threshold for diagnosed GH deficiency, or general interest in "optimization" approaches seen in adult biohacking communities. Each of these concerns deserves a direct response.

For childhood obesity, the FDA approved liraglutide 3 mg (Saxenda) for patients aged 12 and older and semaglutide 2.4 mg (Wegovy) for patients aged 12 and older based on dedicated pediatric trials. The STEP TEENS trial (N=201, ages 12 to 17) showed semaglutide 2.4 mg produced a 16.1% reduction in BMI at 68 weeks versus a 0.6% increase in the placebo group (P<0.001) [10]. These are drugs with pediatric safety data. AOD-9604 is not.

For short stature not meeting GH deficiency criteria, the appropriate evaluation pathway is through a pediatric endocrinologist using established growth charts, bone age assessment, and validated GH stimulation testing per Endocrine Society guidelines, not through an unapproved compounded peptide.

For families interested in "optimization," the evidence base for any growth-axis peptide in healthy children under 12 does not exist. Healthy children with normal growth velocity have no clinical indication for GH-axis intervention of any kind.